SC4HD, the new international consortium to develop a cell therapy for Huntington Disease
Updated: Jul 23, 2020
SC4HD comprises a group of clinicians and scientists actively involved in the development of cell therapy for Huntington's disease. It gathers members from different centers of scientific excellence, distributed in 5 countries and 2 continents.
The consortium aims to provide guidance and guidelines for preclinical testing, clinical development and delivery of cell therapies to facilitate progress, as well as to generate a robust clinical development plan. The group is guided by a policy of open sharing of data, protocols and reagents, and participates in regular meetings. Patient input regarding stem cell based therapies in the context of other clinical trials and drugs are an important component of this effort.